Marin Muhtarov

Marin Muhtarov

Auto-generated profile, based on publicly available information

Marin Muhtarov

Affiliation Multi-Profile Hospital for Active Treatment “Kardzhali”, Gastroenterology Ward, Khardzhali, Bulgaria

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FTFrancesca Tamarozzi
Francesca Tamarozzi
OAOkan Akhan
Okan Akhan
CCCarmen Michaela Cretu
Carmen Michaela Cretu
KVKamenna Vutova
Kamenna Vutova
DADevrim Akinci
Devrim Akinci
Andriano CasulliAndriano Casulli
Andriano Casulli

17 September 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FTFrancesca Tamarozzi
Francesca Tamarozzi
JHJohn Horton
John Horton
MMMarin Muhtarov
Marin Muhtarov
Michael RamharterMichael Ramharter
Michael Ramharter
MSMar Siles-Lucas
Mar Siles-Lucas
EBEnrico Brunetti
Enrico Brunetti
Cystic (CE) and alveolar (AE) echinococcosis are chronic, neglected parasitic diseases burdened by high morbidity and, for AE, by high mortality, if left untreated. CE and AE have a widespread distribution, including Europe. Albendazole (ABZ), a broad-spectrum benzimidazole drug widely used to treat parasitic infections, is the drug of choice for the management of CE and AE, and is parasitostatic on echinococcal metacestodes. In Europe, ABZ is licensed for interrupted “cyclic” treatment, for a maximum of 3 cycles. However, better efficacy with no increased side effects has been shown when the drug is administered continuously and for longer periods. Current international recommendations, on the basis of clinical, pharmacological, and biological studies, recommend continuous administration of ABZ for months to years for the treatment of CE and AE, and this schedule has been widely in use for the past 20 years. However, in Europe this internationally recommended schedule, with the exception of France, is technically “off-label”, and, as such, requires an informed consent by the patient and, in some countries, even precludes the reimbursement of the drug cost. Adding to the very high cost of the drug, frequent “out-of-stock” situation, and packaging format impractical for long therapies, these conditions put patients with CE and AE regularly at risk of treatment discontinuation and disease progression. European regulations envisage variations to marketing authorization, but postauthorization studies should be carried out by the holder of the license of the drug, in the form of randomized controlled trials. While such studies do not seem feasible and would probably not be ethically justified for CE and AE, European regulations envisage other possibilities in particular situations, which apply to CE and AE, but there is limited interest to invest in this perspective. We urge a coordination between stakeholders to find effective and feasible ways to take action to revise the benzimidazole dosage regimens for CE and AE and to ensure a fair, regular, and easy access to the appropriate treatment to those suffering from these serious diseases.

21 January 2017 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
IMIrina Marinova
Irina Marinova
MSMarkus Spiliotis
Markus Spiliotis
Junhua WangJunhua Wang
Junhua Wang
MMMarin Muhtarov
Marin Muhtarov
ICIlias Chaligiannis
Ilias Chaligiannis
GBGhalia Boubaker
Ghalia Boubaker

7 January 2002 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
LTL. Tankova
L. Tankova
KYK. Yoncheva
K. Yoncheva
MMM. Muhtarov
M. Muhtarov
HKH. Kadyan
H. Kadyan
VDV. Draganov
V. Draganov

6 April 2016 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
MMMarin Muhtarov
Marin Muhtarov
IRIskra Georgieva Rainova
Iskra Georgieva Rainova
FTFrancesca Tamarozzi
Francesca Tamarozzi
Cystic echinococcosis (CE) is a clinically complex chronic parasitic disease, management options for which include surgery, percutaneous treatments, and treatment with albendazole (ABZ) for active cysts, and the “Watch-and-Wait” approach for uncomplicated, inactive cysts. We examined, retrospectively, the clinical management of 334 patients with hepatic CE from the southeastern Rhodope region of Bulgaria between 2004 and 2013. Cysts were reclassified according to the World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) on the basis of ultrasound reports and images. The majority (62.3%) of uncomplicated cysts were CE1, 66% of which were treated surgically. Of all interventions, 5% were performed on inactive uncomplicated CE4–CE5 cysts. About half (47.6%) of these cysts were therefore treated inappropriately, exposing patients to unnecessary treatment-related risks and the health system to unnecessary costs. No management change was observed after the publication of the WHO-IWGE Expert Consensus recommendations in 2010. In Bulgaria, ABZ is still used in interrupted cycles as this is reimbursed, and peri-interventional chemoprophylaxis was not administered in the majority of surgical patients. Efforts are needed to introduce the WHO-IWGE classification and management recommendations and to encourage reception of state-of-the-art practices by public health regulatory bodies to improve patient quality of care and optimization of health resources.